KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesChange in Working CapitalExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet Equity Issued and RepurchasedNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Novartis Ag (NVS) over the last 17 years, with Q4 2025 value amounting to $1.8 billion.

  • Novartis Ag's Net Cash Flow rose 20038.13% to $1.8 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$600.0 million, marking a year-over-year increase of 6332.52%. This contributed to the annual value of -$600.0 million for FY2025, which is 6332.52% up from last year.
  • As of Q4 2025, Novartis Ag's Net Cash Flow stood at $1.8 billion, which was up 20038.13% from $2.9 billion recorded in Q3 2025.
  • Over the past 5 years, Novartis Ag's Net Cash Flow peaked at $5.5 billion during Q3 2024, and registered a low of -$10.2 billion during Q2 2022.
  • Its 5-year average for Net Cash Flow is -$84.4 million, with a median of -$250.5 million in 2023.
  • Its Net Cash Flow has fluctuated over the past 5 years, first skyrocketed by 91682.97% in 2021, then crashed by 88632.15% in 2022.
  • Quarter analysis of 5 years shows Novartis Ag's Net Cash Flow stood at $5.2 billion in 2021, then crashed by 128.0% to -$1.5 billion in 2022, then surged by 120.0% to $291.0 million in 2023, then tumbled by 730.93% to -$1.8 billion in 2024, then surged by 200.38% to $1.8 billion in 2025.
  • Its Net Cash Flow was $1.8 billion in Q4 2025, compared to $2.9 billion in Q3 2025 and -$792.0 million in Q2 2025.